Your browser doesn't support javascript.
loading
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.
Taher, Ali T; Karakas, Zeynep; Cassinerio, Elena; Siritanaratkul, Noppadol; Kattamis, Antonis; Maggio, Aurelio; Rivella, Stefano; Hollaender, Norbert; Mahuzier, Bruyère; Gadbaw, Brian; Aydinok, Yesim.
Afiliação
  • Taher AT; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Karakas Z; Department of Pediatric Hematology and Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
  • Cassinerio E; Università di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
  • Siritanaratkul N; Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Kattamis A; First Department of Pediatrics, University of Athens, Athens, Greece.
  • Maggio A; Campus of Haematology Franco e Piera Cutino Azienda Ospedaliera Ospedali Riuniti Villa Sofia V. Cervello, Palermo, Italy.
  • Rivella S; Department of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Hollaender N; Novartis Pharma AG, Basel, Switzerland.
  • Mahuzier B; Novartis Pharma S.A.S., Rueil Malmaison, France.
  • Gadbaw B; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
  • Aydinok Y; Ege University Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey.
Blood ; 131(2): 263-265, 2018 01 11.
Article em En | MEDLINE | ID: mdl-29097381

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talassemia / Talassemia beta Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talassemia / Talassemia beta Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article